Calculation of Filing Fee Tables | |||
S-8 | |||
AbbVie Inc. | |||
Table 1: Newly Registered Securities |
|---|
Security Type | Security Class Title | Fee Calculation Rule | Amount Registered | Proposed Maximum Offering Price Per Unit | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee | |
|---|---|---|---|---|---|---|---|---|
| 1 | Other | Deferred Compensation Obligations | Other | $ 275,000,000.00 | 0.0001531 | $ 42,102.50 | ||
| 2 | Other | Deferred Compensation Obligations | Other | $ 75,000,000.00 | 0.0001531 | $ 11,482.50 | ||
Total Offering Amounts: | $ 350,000,000.00 | $ 53,585.00 | ||||||
Total Fee Offsets: | $ 0.00 | |||||||
Net Fee Due: | $ 53,585.00 | |||||||
Offering Note |
1 | The deferred compensation obligations are unsecured obligations of AbbVie Inc. (the "Registrant") to pay deferred compensation in the future pursuant to the terms of the AbbVie Deferred Compensation Plan (the "DCP"). The maximum aggregate offering price is estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(h) of the Securities Act of 1933, as amended (the "Securities Act"), based upon an estimate of the amount of compensation participants may defer under the DCP. | ||||||
2 | The deferred compensation obligations are unsecured obligations of the Registrant to pay deferred compensation in the future pursuant to the terms of the AbbVie Deferred Compensation Plan Plus (the "DCP Plus"). The maximum aggregate offering price is estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(h) of the Securities Act, based upon an estimate of the amount of compensation participants may defer under the DCP Plus. | ||||||
